Secondary tabs
Contact details
Maria Giner-Soriano mginer@idiapjgol.info
Main
Talita Duarte-Salles tduarte@idiapjgol.org
Alternate
Publications
Data source publications
- Recalde M, Rodríguez C, Burn E, Far M, García D, Carrere-Molina J, Benítez M, Moleras A, Pistillo A, Bolíbar B, Aragón M. Data resource profile: the information system for research in primary care (SIDIAP). International Journal of Epidemiology. 2022 Dec 1;51(6):e324-36.
- Maria Giner-Soriano, Dan Ouchi, Roser Vives, Carles Vilaplana-Carnerero, Andrea Molina, Antoni Vallano and Rosa Morros. Effectiveness and safety of oral anticoagulants for non-valvular atrial fibrillation: a population-based cohort study in Primary Health Care in Catalonia. Frontiers in Pharmacology 2023;14:1237454
- Bolíbar B, Avilés FF, Morros R, del Mar Garcia-Gil M, Hermosilla E, Ramos R, Rosell M, Rodríguez J, Medina M, Calero S, Prieto-Alhambra D. SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research. Medicina clinica. 2012 May 19;138(14):617-21.
- Fernández-García S, Moragas Moreno A, Giner-Soriano M, Morros R, Ouchi D, García-Sangenís A, Monteagudo M, Monfà R, Llor C. Urinary Tract Infections in Men in Primary Care in Catalonia, Spain. Antibiotics (Basel). 2023 Nov; 12(11).
- Raventós B, Català M, Du M, Guo Y, Black A, Inberg G, Li X, López-Güell K, Newby D, de Ridder M, Barboza C, Duarte-Salles T, Verhamme K, Rijnbeek P, Prieto Alhambra D, Burn E. IncidencePrevalence: An R package to calculate population-level incidence rates and prevalence using the OMOP common data model. Pharmacoepidemiol Drug Saf. 2024 Jan; 33(1):e5717
Studies
List of studies that have been conducted using the data source
- Cost-Effectiveness Analysis of Treatment with Statins in Primary Prevention of Vascular Events (EPREV project)
- Measurement of the effectiveness of statins in vascular morbidity and mortality reduction in the population without history of vascular disease but with intermediate risk and ankle-brachial Index < 0.9 in primary care setting (MARIA study)
- Effectiveness of an Interventional to Improve the Adequacy of the Indication of Lipid Lowering Treatment in Primary Prevention: Randomized Clinical Trial (Adequacy of Lipid Treatment)
- Drugs as risk factors of unexplained sudden cardiac death (SCD). A case-control study
- Riesgo de cáncer colorrectal asociado al uso de medicamentos: estudio de casos y controles (IJG-CCR-2015)
- Riesgo de accidente vascular cerebral asociado al uso de medicamentos: estudio de casos y controles (IJG-AVC-2015)
- A multi-database cohort study to assess the incidence rates of colorectal hyperplasia among hypertensive patients
- Assessment of cardiovascular effects of non-insulin glucose-lowering agents. Major cardiovascular events in new users of non-insulin glucose-lowering agents: observational longitudinal study in the Catalan population-based electronic health record database, SIDIAP, 2010-2015
- Use of antidepressant drugs and its association with risk of stroke, frequency of hospitalization, and mortality in an elderly population: a descriptive and analytic cohort study
- ADVANCE POC I Risk pillar - Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case: Incidence rates of safety outcomes of whole-cell pertussis and acellular pertussis vaccines in pre-school children
- ADVANCE POC Study Protocol - Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case. Coverage rates of acellular and whole-cell pertussis-containing vaccines in preschool children (ADVANCE Coverage POC)
- European Program of Post-Authorization Safety Studies for Protelos®/Osseor® through EU-ADR Alliance
- Study about the results of the addition of a sulfonylurea, DPP4 inhibitors or SGLT2 inhibitors as a second antidiabetic drug in patients with diabetes mellitus type 2 in treatment with metformin and insufficient glycemic control. (eControl Met +)
- Multinational Observational Database Study on Imminent Osteoporotic Fracture Risk: Stage 1 (IFRISK)
- Cilostazol Drug Utilisation Study
- Risk of lactic acidosis associated with metformin use in patients with type 2 diabetes and moderate-severe chronic kidney disease: a case-control study (ALIMAR-C2)
- EMIF Use Case 17 - Investigating the relationship in paediatric population between dosing of antibiotics (prescribed, dispensed or administered) and patient’s weight. (EMIF UC17)
- Exposure and coverage to routine schedule vaccines in different EU countries (ADVANCE-POC2)
- Estimating prevalence and incidence of acute myocardial infarction in a set of heterogeneous sources of observational health data collaborating in the EMIF Platform
- Apixaban drug utilization study in Stroke prevention in atrial fibrillation (SPAF)
- USE OF PSYCHOTROPIC DRUGS IN CHILDREN AND ADOLESCENTS IN CATALONIA. A cohort study with real world data from the electronic primary health care record from 2007-2017. (PEPSICAT)
- Drug utilization study of mirabegron (Betmiga®) using real-world healthcare databases from the Netherlands, Spain, United Kingdom and Finland (Mirabegron DUS)
- COMPARABILITY OF POPULATION DEFINITIONS WITHIN & BETWEEN GLOBAL DATABASES – DEVELOPING TOOLS FOR OBSERVATIONAL RESEARCH (ACO Population Definitions)
- A Joint Drug Utilisation Study (DUS) of valproate and related substances, in Europe, using databases
- The comparative safety of first-line conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) used for the treatment of rheumatoid arthritis: protocol for a multi-database real-world cohort study
- Utilisation disease-modifying anti-rheumatic drugs (DMARDs) used for the treatment of rheumatoid arthritis: protocol for a multi-database real-world cohort study
- Linaclotide Utilisation Study in Selected European Populations
- Hydroxychloroquine safety and potential efficacy as an antiviral prophylaxis in light of potential wide-spread use in COVID-19: a multinational, large-scale network cohort and self-controlled case series study
- A Retrospective Cohort Study to Assess Drug Utilisation and Long-Term Safety of Galcanezumab in European Patients in the Course of Routine Clinical Care (I5Q-MC-B002)
- Multinational database cohort study to assess RMP specified safety outcomes in association with indacaterol/glycopyrronium bromide in Europe
- European non-interventional post-authorization safety study related to serious cardiovascular events of myocardial infarction and stroke, and all-cause mortality for romosozumab by the EU-ADR Alliance
- EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO ADHERENCE TO THE RISK MINIMIZATION MEASURES FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE
- EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU ADR ALLIANCE
- VALIDATION STUDY PROTOCOL (OP0007) FOR THE EUROPEAN NON-INTERVENTIONAL POST- AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS CARDIOVASCULAR EVENTS OF MYOCARDIAL INFARCTION AND STROKE AND ALL-CAUSE MORTALITY FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0004) AND EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0006)
- Utilisation of dulaglutide in European countries: A cross-sectional, multi-country and multi-source drug utilisation study using electronic health record databases (H9X-MC-B010)
- Multinational, multi-database cohort study to assess adverse cardiovascular and cerebrovascular outcomes and mortality in association with inhaled NVA237 in Europe (NVA237 PASS)
- Multinational, multi-database drug utilization study of inhaled NVA237 in Europe (NVA237 DUS)
- Ranitidine and other histamine H2-receptor antagonists – a drug utilisation study
- Post-Authorisation Safety Study of Agomelatine and the Risk of Hospitalisation for Acute Liver Injury
- Project Sc(y)lla: SARS-Cov-2 Large-scale Longitudinal Analyses on the comparative safety and effectiveness of treatments under evaluation for COVID-19 across an international observational data network
- Multinational, multi-database drug utilization study of indacaterol/glycopyrronium bromide in Europe
- Sociodemographic, clinical and pharmacological characteristics associated with the prognosis of patients with SARS-CoV-2 infection (Características sociodemográficas, clínicas y farmacológicas asociadas con el pronóstico en pacientes con infección por SARS-CoV-2)
- The risk of musculoskeletal adverse outcomes after treatment with endocrine blocking treatments for breast cancer (MSKAI)
- Linaclotide Safety Study for the Assessment of Diarrhoea—Complications and Associated Risk Factors in Selected European Populations with IBS-C
- Safety and Incidence of Side Effects in a Cohort of Postmenopausal Women Prescribed Ospemifene Relative to Patients Diagnosed with but not Treated for Vulvar and Vaginal Atrophy (VVA) and Patients on Selective Oestrogen Receptor Modulators (SERMs) for Oestrogen-deficiency Conditions or Breast Cancer Prevention – A Post-Authorisation Safety Study
- Comparative risk of the incident cancer between histamine-2 receptor antagonists (Risk of cancer between H2RAs)
- An Observational Post-Authorisation Safety Study of Lesinurad Patients (SATURATES)
- Study of exposure and use patterns of alternatives to ranitidine-containing medicines in patients treated with ranitidine (Ranitidine)
- Comparative safety study of tramadol and codeine users: a population-based cohort study
- Natural history of coagulopathy and use of anti-thrombotic agents in COVID-19 patients and persons vaccinated against SARS-CoV-2
- Monitoring safety of Spikevax in pregnancy: an observational study using routinely collected health data in five European countries (COVID-19)
- Post-Authorization Active Surveillance Safety Study Using Secondary Data to Monitor Real-World Safety of Spikevax in Europe (COVID-19)
- Assessment of Pregnancy Outcomes in Women Exposed to Modafinil/Armodafinil: Pregnancy Database Study
- Systemic glucocorticoids in the treatment of COVID-19 and risks of adverse outcomes in COVID-19 patients in the primary and secondary care setting (Corticosteroids in COVID19)
- Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU
- Drug Utilization Study (DUS) and post authorization safety study (PASS) on the fixed combination Tramadol-Dexketoprofen (DKP-TRAM)
- ASSOCIATION BETWEEN THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME (TTS) OR THROMBOEMBOLIC EVENTS, AND COVID-19 VACCINES
- Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
- Post-Authorisation Active Surveillance Study of Myocarditis and Pericarditis Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
- PCSCVM003617/ A Real-World Database Study of Canagliflozin Utilization in Type 1 Diabetes Patients Over Time among European Countries
- Impact of medication adherence on mortality and cardiovascular morbidity: a population-based retrospective cohort study. IMPACT study
- Risks of pharmacological interactions of direct oral anticoagulants: thrombotic and hemorrhagic events leading to hospital admission in Catalonia. (IFACOD)
- Uso de fármacos en mujeres embarazadas y lactantes. Consecuencias en la salud de estas mujeres y en la de su descendencia (Drug use in pregnant and breastfeeding women. Outcomes in the health of the women and the offspring) (Drug use during pregnancy and breastfeeding)
- A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19)
- Non-interventional post-authorization multi-database safety study to characterize the risk of angioedema and other specific safety events of interest in association with use of Entresto® (sacubitril/valsartan) in adult patients with heart failure
- An Observational Post-Authorization Safety Study to Assess the Safety of Ad26.COV2.S Using European Healthcare Data through VAC4EU (COVID-19)
- A Drug Utilisation Study extension (DUS ext.) of valproate and related substances, in Europe, using databases (VALNAC09343)
- Non-interventional post-authorization multi-database safety study to assess the risk of myotoxicity, hepatotoxicity and acute pancreatitis in statin-exposed heart failure patients with or without concomitant use of sacubitril/valsartan (Entresto®)
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients who Initiated Exenatide as Compared with those who Initiated Other non-Glucagon-Like Peptide 1 Receptor Agonists based Glucose Lowering Drugs (EXCEED)
- Management of Urinary Tract Infections in Catalonia: adequacy of diagnostic and therapeutic management, predictors of complications and impact of suppressive therapies on the severity of potentially serious infections (PROJECT ITUCAT)
- Drug utilization of Intrarosa (6.5 mg prasterone pessary) in European Countries (ERC-243)
- Safety of Paxlovid During Pregnancy
- Safety of Paxlovid Among Patients with Moderate or Severe Hepatic or Renal Impairment
- Effectiveness of heterologous and booster Covid-19 vaccination in 5 European countries, using a cohort approach in children and adults with a full primary Covid-19 vaccination regimen (Covid Vaccines Effectiveness (CoVE))
- Rapid Safety Assessment of SARS-CoV-2 vaccines in EU Member States using electronic health care datasources (CVM Covid19-Vaccine-Monitor-EHR)
- Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (ACCESS-BGR)
- Evaluation of the effectiveness of pregnancy prevention programme (PPP) for oral retinoids (acitretin, alitretinoin, and isotretinoin): a European before-after drug utilization study (DUS) using secondary data
- Multi-country non-interventional study on the effectiveness and safety of Empagliflozin in adult patients with type 2 diabetes in Europe and Asia
- DARWIN EU® Prevalence of rare blood cancers in Europe
- DARWIN EU® Drug utilisation of valproate-containing medicinal products in women of childbearing potential
- Assessing exposure to cardiovascular therapy, anxiety depressive syndrome treatment and anti-infectives during pregnancy and breastfeeding (Drug exposure in pregnancy and breastfeeding)
- DARWIN EU® DUS of Antibiotics in the ‘Watch’ category of the WHO AWaRe classification of antibiotics for evaluation and monitoring of use
- DARWIN EU® - Background rates of serious adverse events to contextualise safety assessments in clinical trials and non-interventional studies in adolescent and adult patients with severe asthma
- Post-authorisation Safety Study of Rimegepant in Patients with Migraine and History of Cardiovascular Disease in European Countries
- Utilization of antidementia treatments: a large multinational-network population-based study.
- Xarelto Paediatric VTE PASS Drug Utilization Study: An observational, longitudinal, multi-source drug utilization safety study to evaluate the drug use patterns and safety of rivaroxaban oral suspension in children under two years with venous thromboembolism (XAPAEDUS)
- mRNA-1273-P910: Clinical course, outcomes and risk factors of myocarditis and pericarditis following administration of Moderna vaccines targeting SARS-CoV-2.
- DARWIN EU® Multiple myeloma: patient characterisation, treatments and survival in the period 2012-2022
- DARWIN EU® Use of take-home naloxone for opioid overdose treatment
- DARWIN EU® Drug utilization study of prescription opioids
- DARWIN EU® Treatment patterns of drugs used in adult and paediatric population with systemic lupus erythematosus
- A Non-Interventional Multi-Country Post-Authorisation Safety Study (PASS) to Assess the Incidence of Serious Infections & Malignancies in Systemic Lupus Erythematosus (SLE) Patients Exposed to Anifrolumab (SIMA PASS)
- DARWIN EU® EHDS Use Case: Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV-2 in the context of the OMICRON variant
- DARWIN EU® Drug utilisation study of medicines with prokinetic properties in children and adults diagnosed with gastroparesis
- EHDS2 Pilot Use Case: Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV-2 during the Omicron period.
- Incidence, prevalence, and characterisation of medicines with suggested drug shortages in Europe
- DARWIN EU® Natural history of dermatomyositis (DM) and polymyositis (PM) in adults and paediatric populations
- DARWIN EU® Rates of occurrence of treatment-related intercurrent events in patients with major depressive disorder
- DARWIN EU® Effectiveness of COVID-19 vaccines on severe COVID-19 and post acute outcomes of SARS-CoV-2 infection
- Data characterization of population-based data sources: ConcePTION pipeline
- DARWIN EU® Age specific incidence rates of RSV related disease in Europe
- DARWIN EU® Monitoring prescription of medicines for public health emergencies at risk of shortages
- Post-Authorisation Safety Study of Comirnaty Original/Omicron BA.1 and Comirnaty Original/Omicron BA.4-5 in Europe
- DARWIN EU® Effectiveness of Human Papillomavirus Vaccines (HPV) to prevent cervical cancer
- A real-world observational study of treatment patterns and outcomes for patients with neuromyelitis optica spectrum disorders (NMOSD) treated with inebilizumab (UPLIZNA) in Europe
- DARWIN EU® Comparing direct and indirect methods to estimate prevalence of chronic diseases using real-world data
- DARWIN EU® – Frailty and polypharmacy among adults with selected cancers at the time of diagnosis
- An Observational Multi-Country Post-Authorisation Safety Study to Evaluate the Risk of Serious Adverse Cardiovascular Events in Adolescent and Adult Patients with Severe Asthma taking Tezepelumab (TRESPASS)
- SAFETY-VAC: Network of Data Sources for Vaccine Safety Evaluation
- ADEPT: The utilisation of antiseizure medications in pregnant women, other women of childbearing potential, and men: a multi-database study from 7 European countries
- DARWIN EU® – Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications
- DARWIN EU® - Drug Utilisation Study on GLP-1 Receptor Agonists
- SAFETY-VAC: Background incidence estimation of flares of pre-existing chronic diseases using pan-European electronic healthcare data sources. (SAFETY VAC)
- ADEPT: feasibility of estimating the risk of adverse pregnancy, neonatal and child outcomes following either in utero ASM exposure through the mother, or peri-conceptional ASM exposure through the father
- DARWIN EU® - Background incidence rates of selected vaccine adverse events of special interest (AESIs) in Europe
- DARWIN EU® - Suicidality following exposure to doxycycline
- SAFETY-VAC: Phenotype proposal and rates of immunocompromised populations in real-world data sources.
- DARWIN EU® - Incidence of suicidality in patients with specific chronic skin conditions
- VAC4EU Postauthorisation Safety Study of BIMERVAX® Vaccine in Europe
- DARWIN EU® - Azathioprine - user characteristics
- DARWIN EU® - Antipsychotic prescribing in the general population in Europe: a descriptive analysis of trends and patient characteristics
- DARWIN EU® - DUS Characterising STOPP criteria medication use in people with recurrent falls
- VAC4EU Postauthorisation Effectiveness Study of BIMERVAX® Vaccine in Europe
- A Drug Utilization Study to Evaluate the Effectiveness of Risk Minimization Measures (RMMs) for Abrocitinib in the EU Using Electronic Healthcare Data (B7451085)
- DARWIN EU® - Incidence of myoclonus in heart failure: a descriptive analysis in patients treated with sacubitril/valsartan and other treatments
- DARWIN EU® - Antipsychotic prescribing in people with dementia in Europe: a descriptive analysis of trends and patient characteristics
- A Post-Authorisation Safety Study (PASS) of ABRYSVO (Respiratory Syncytial Virus Stabilised Prefusion Subunit Vaccine) in Pregnant Women and their Offspring in a Real World Setting in Europe and UK
- A post-authorisation safety study of ABRYSVO in immunocompromised, or renally or hepatically impaired adults aged 60 years and older in a real world setting in Europe and UK
- DARWIN EU® -Drug utilisation of salbutamol products for inhalation and therapeutic alternative inhalation products
- DARWIN EU® - Suicidality incidence rates in adult male patients and in patients treated with finasteride and dutasteride
- DARWIN EU® - Characterisation of exposure to acitretin and purpura and related conditions
- DARWIN EU® - Prevalence of hypertrophic cardiomyopathy (HCM) and obstructive hypertrophic cardiomyopathy (oHCM) in six European countries
- DARWIN EU® – Incidence rates of venous thromboembolic events in patients with selected cancers
- DARWIN EU® - Association of venous thromboembolism with non-steroidal anti-inflammatory drug use in women 15-49 years using hormonal contraceptives
- DARWIN EU® Drug Utilisation Study of prescription opioids
- Post-Authorization Safety Study to Assess the Effectiveness of the Newly Implemented Risk Minimization Measures for Topiramate: Drug Utilization Study
- DARWIN EU® – Utilisation of commonly used benzodiazepines during pregnancy and the incidence of pregnancy losses
- Association between previous biologic therapy exposure and incidence of life-threatening infections in patients with rheumatoid arthritis and psoriasis. A population-based cohort study.
- DARWIN EU® - Clozapine and the incidence of agranulocytosis over time
- Use of antipsychotics in children and adolescents in the Spanish National Health System: network project with real-world data from five Autonomous Communities to inform evidence-based health policies (Children and Adolescents Antipsychotic Research for Evidence-based Strategies – CARES Project)